Global Biopharmaceutical CMO and CRO Market: Current Analysis and Forecast (2022-2028)

Global Biopharmaceutical CMO and CRO Market: Current Analysis and Forecast (2022-2028)

Biopharmaceutical CMO is the abbreviation used for a biopharmaceutical contract manufacturing organization which is an organization that caters to the biopharmaceutical industry and provides clients services, from drug development to manufacturing. A contract research organization is a service biotechnology industries in the form of outsourced pharmaceutical research services. The rising number of chronic diseases and increasing investments of the major biopharmaceutical industry in the upsurging of production capabilities attributes to the market growth of the biopharmaceutical CMO and CRO market.

The Biopharmaceutical CMO and CRO Market are expected to grow at a steady rate of around 7% owing to the increased participation of major companies and the rising number of CROs and CMOs in the market. For instance, in January 2023, RQM+ launched its clinical trial services division to complete its complement of medtech contract research organization (CRO) services.

• Based on the source, the market has been bifurcated into mammalian and non-mammalian. Among them, the mammalian segment holds a dominant share of the market in 2020. Mammalian cells are used in the production of recombinant proteins that have a similar structure as that of human cells. Therefore, the use of mammalian cells in recombinant DNA technology and in the production of monoclonal antibodies has increased. This is the factors responsible for the domination of the segment.
• Based on the services, the market has been bifurcated into contract manufacturing and contract research. Among them, the contract research segment is expected to witness the fastest growth during the forecast period. The rise in the number of clinical trials and the surging demand for gene therapy in the treatment of rare diseases are the important factors driving the growth of the CRO segment in the market. Furthermore, the entrance of new and small-scale players also contributed to the growth of the segment. For example, in 2021, the France-based CRO start-up Zanteris bring customized solutions for the management of clinical trials by using experienced clinical project/clinical operations managers, and flexible & optimal support to the CRO, pharmaceutical, and biotechnology industries.
• Based on the product, the market has been categorized into biologics and biosimilars. Among them, the biologics category is projected to have a predominant share in the market. The biologics require continuous purification, usually using single-use reactors, and require complex manufacturing steps which encourages the companies to outsource the production of the biologics from CMOS to reduce the operational cost is an important factor for catalyzing the growth of the segment.
• For a better understanding of the market adoption of the biopharmaceutical CMO and CRO industry, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America is anticipated hold a dominant market share in 2020. This is mainly due to the presence of major market players in the region, high research & development investment in biotechnology is responsible for the growth of the market in the region. For instance, in September 2022, The United States announced New Investments and Resources to Advance President Biden’s National Biotechnology and Biomanufacturing Initiative.
• Some of the major players operating in the market are Boehringer Ingelheim International GmbH, Inc.; Lonza; Rentschler Biopharma SE; JRS PHARMA; ProBioGen AG; FUJIFILM Diosynth Biotechnologies U.S.A., Inc.; TOYOBO CO., LTD.; Samsung Biologics; Thermo Fisher Scientific Inc; and AbbVie Inc.